OptiNose (OPTN) Commences Proposed Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/18/2026
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Oil touches $110 a barrel for first time since May on Middle East, Russia supply fears
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Appleās first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
- Yorkville Ives: 'GameStop Is Becoming the Hobby's Intake Network'
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Micron Technology stock drops on China chip news and labor dispute
- Brazil's Bolsonaro, Lula face off in first debate as supporters fill streets
- Truist Financial to sell $7.7B LightStream loan portfolio to Carlyle
Optinose Announces Proposed Public Offering of Common Stock
August 13, 2020 4:26 PM EDTYARDLEY, Pa., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Optinose (NASDAQ: OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, today announced the commencement of a proposed underwritten public offering of shares of its common stock. All of the shares of common stock will be offered by Optinose. Optinose expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the total number of shares of common stock.
Optinose intends to use the net proceeds of the offering for working capital and... More



